Lannett Company has received FDA approval for its sumatriptan nasal spray, a generic version of GSK’s Imitrex nasal spray. The company cites IMS statistics showing that US sales of sumatriptan nasal spray totaled $62 million in 2015.
Lannett CEO Arthur Bedrosian commented, “We believe our sumatriptan nasal spray USP, 5 mg/spray and 20 mg/spray will be a first-to-market generic product. Producing nasal delivery medications requires unique expertise and facilities that few possess. Our sumatriptan nasal spray product was developed by Summit Biosciences Inc. and will be manufactured at its state-of-the-art facility located on the University of Kentucky’s Coldstream Research Campus. We expect to commence marketing the product in the next several months.”
Read the Lannett press release.
